Transarterial chemoembolization plus camrelizumab is an effective and tolerable bridging therapy for patients with intermediate‑stage hepatocellular carcinoma: A pilot study

Transarterial chemoembolization (TACE) has been reported to synergize with camrelizumab in the treatment of hepatocellular carcinoma (HCC). The present study aimed to explore the potential of TACE and camrelizumab as a bridging therapy prior to surgery for patients with HCC. For this purpose, 11 pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Huo, Haoran, Wang, Xiaoying, Xu, Shan, Niu, Xiaotong, Cheng, Limin, Yuan, Zengjiang, Huo, Shuang, Fang, Pingping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10534277/
https://www.ncbi.nlm.nih.gov/pubmed/37780547
http://dx.doi.org/10.3892/ol.2023.14052

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10534277/
https://www.ncbi.nlm.nih.gov/pubmed/37780547
http://dx.doi.org/10.3892/ol.2023.14052

Ejemplares similares